The role of 18F-PSMA-1007 PET/CT is novel in these clinical scenarios; however, its ability to detect prostate cancer in patients with low PSA levels, a common limitation of conventional imaging techniques, may enable earlier and more targeted interventions [5]. This evidence concerns the gene FOLH1 and prostate carcinoma.